Litigation Details for UCB, Inc. v. Catalent Pharma Solutions Inc. (E.D. Ky. 2021)

✉ Email this page to a colleague

The small molecule drug covered by the patent cited in this case is ⤷ Subscribe .

Subscribe to access the full database, or Subscribe
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-05-12	59		New Drug Applications 1 U.S. Patent No. RE38,551 (the “ ‘551 Patent”). 2 VIMPAT® is an antiepilectic…dispute. On July 6, 2004, the U.S. Patent Office issued a patent to Dr. Harold Kohn, which described …product that is protected by a patent, such as lacosamide, before the patent expires. In 1984, however, … development by allowing “patent holders to extend the term of their patent up to five years for delays…would constitute patent infringement under Section 271(a) of the United States Patent Act, 5 and this	External link to document
2021-11-28	60		interest in United States Reissued Patent No. RE38,551 (“the ‘551 Patent”), which claims the chemical compound… claim for patent infringement because the product is a patented invention and the patent term has not… sells, or imports a patented invention without authority “infringes the patent.” However, the Hatch-… for patent infringement.” [Id.] They also argue the complaint fails to state a claim for patent infringement…any patented invention, within the United States or imports into the United States any patented	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document